COMMUNIQUÉS West-GlobeNewswire

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

18/11/2024 - 14:30

Actively Exploring Partnership for Alzheimer’s Development Supplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company [...]

Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer

18/11/2024 - 14:30

Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugs Appointment initiates Cassava’s commercial readiness strategy as the Company prepares for [...]

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

18/11/2024 - 14:30

FLORHAM PARK, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that the Nasdaq Listing Qualifications Hearings Panel ( [...]

Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference

18/11/2024 - 14:30

BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted [...]

Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit

18/11/2024 - 14:30

SOLANA BEACH, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people [...]

FOXO TECHNOLOGIES INC.’S BOARD OF DIRECTORS ANNOUNCES SPECIAL MEETING OF SHAREHOLDERS

18/11/2024 - 14:30

MINNEAPOLIS, MN, Nov. 18, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), will hold a Special Meeting of its Shareholders at 10.30am EST on Friday, November 29, 2024. The [...]

Cerevance Doses First Patient in Pivotal Phase 3 ARISE Trial of Solengepras for Treatment of Parkinson’s Disease

18/11/2024 - 14:30

Solengepras is a potentially first-in-class, oral, non-dopaminergic investigational therapy in development for Parkinson’s disease ARISE will evaluate the efficacy of solengepras as an adjunctive therapy to levodopa and [...]

Aclaris Therapeutics Announces $80 Million Private Placement

18/11/2024 - 14:10

WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno- [...]

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

18/11/2024 - 14:10

- Enhances Aclaris’ pipeline with complementary biologics portfolio - - Expands leadership team with addition of seasoned biotech executives - - Management to host conference call today at 8:30 AM ET - WAYNE, Pa., Nov. [...]

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

18/11/2024 - 14:05

27-year-old African American-Asian Woman with Active Lupus Nephritis Achieved DORIS Clinical Remission; Patient Remains On-study, in Clinical Remission, and Free of All Immunosuppressive Therapies Patient Treated with [...]

Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device

18/11/2024 - 14:01

Management to host business update call today at 9:00am ET NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on [...]

Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

18/11/2024 - 14:00

Patient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utilizing latest treatment guidelines for portal hypertension in MASH cirrhosis Blinded central review system can be [...]

Medis Celebrates 35th Anniversary

18/11/2024 - 14:00

Marking the company’s 35 years of bringing innovative therapies to patients across Central and Eastern Europe. 18 countries, 400 highly skilled employees, 100 novel medicines, a large assortment of medical products A [...]

Sharps Regains Nasdaq Listing Compliance

18/11/2024 - 14:00

NEW YORK, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe [...]

Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy

18/11/2024 - 14:00

Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the University of Edinburgh to [...]

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

18/11/2024 - 14:00

Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancer Allarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate stenoparib’s clinical development toward [...]

Rectify Pharma Presents Preclinical Data Supporting Development of Lead Candidate RTY-694 at The Liver Meeting® 2024

18/11/2024 - 14:00

RTY-694 increased protein levels and function of ABCB4 and BSEP in primary hepatocytes, two transporters that play a key role in bile composition and bile flow Data demonstrate the potential of PFMs to restore and [...]

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

18/11/2024 - 14:00

Topline results expected in early January 2025 CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of [...]

CBIH Strengthens Clinical Research Team in Preparation for Launch of Next-Generation Cannabinoid Solutions

18/11/2024 - 14:00

HOUSTON, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) continues to invest in top-tier talent as it prepares to launch its specialized pharmaceutical and nutraceutical [...]